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Abstract
The effectiveness of the caspase-9-based artificial “death switch” as a safety measure for gene therapy based on the erythro-
poietin (Epo) hormone was tested in vitro and in vivo using the chemical inducer of dimerization, AP20187. Plasmids encoding 
the dimeric murine Epo, the tetracycline-controlled transactivator and inducible caspase 9 (ptet-mEpoD, ptet-tTAk and pSH1/
Sn-E-Fv’-Fvls-casp9-E, respectively) were used in this study. AP20187 induced apoptosis of iCasp9-modified C2C12 myoblasts. 
In vivo, two groups of male C57BI/6 mice, 8-12 weeks old, were injected intramuscularly with 5 µg/50 g ptet-mEpoD and 0.5 
µg/50 g ptet-tTAk. There were 20 animals in group 1 and 36 animals in group 2. Animals from group 2 were also injected with 
the 6 µg/50 g iCasp9 plasmid. Seventy percent of the animals showed an increase in hematocrit of more than 65% for more than 
15 weeks. AP20187 administration significantly reduced hematocrit and plasma Epo levels in 30% of the animals belonging to 
group 2. TUNEL-positive cells were detected in the muscle of at least 50% of the animals treated with AP20187. Doxycycline 
administration was efficient in controlling Epo secretion in both groups. We conclude that inducible caspase 9 did not interfere 
with gene transfer, gene expression or tetracycline control and may be used as a safety mechanism for gene therapy. However, 
more studies are necessary to improve the efficacy of this technique, for example, the use of lentivirus vector. 
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The eventual adoption of gene therapy as a routine 
medical procedure requires the development of safe vec-
tors and fail-safe mechanisms to eliminate potential injuries 
to the host, even by removing genetically altered cells. 
The ideal suicide switch should be non-immunogenic and 
non-toxic when not induced and able to trigger cell death, 
independently of tissue type or cell cycle stage. Chemically 
induced dimerization (CID) (1) is a versatile approach to the 
control of gene activity. A panel of inducible suicide genes 
based on Fas and Fas-signaling intermediates such as 
Apaf-1 and caspases 1, 3, 8, and 9 have been success-
fully developed (2-7). In our studies, an inducible caspase 
9 (iCasp9) was the most CID-sensitive one (3, and Spen-
cer DM, unpublished results). The iCasp9 consists of two 
mutated FK506-binding protein (FKBP)-12 domains, both 
containing an F36V mutation, fused to the procaspase 9 
cDNA under the control of the broadly constitutive Sralpha 
promoter. The iCasp9 can be dimerized with AP1903 or 
AP20187, which are nontoxic, cell-permeable and synthetic 
dimeric FK506 analogues that have been designed to re-
duce interactions with endogenous FKBPs, while enhancing 
binding to the mutated FKBP variant (8). Administration of 
the dimerizing drug results in the aggregation of iCasp9 
molecules, leading to their activation. Caspase 9 will sub-
sequently activate downstream effector caspases such as 
caspase 3, and ultimately induce apoptosis (1,3,4,9). The 
drug AP1903, an analogue of AP20187, has been tested 
in 28 normal volunteers and has been shown to be safe 
and well tolerated (10).
The cost and quality of therapeutic protein production 
are major obstacles for the treatment of a large number of 
patients with a wide range of diseases. In this context, gene 
therapy for treating patients with hemophilia using factor IX 
or factor VIII has been increasingly improved, gaining space 
and importance in this field (11-13). Thus, millions of patients 
with chronic anemia caused by kidney diseases, cancer, 
Inducible caspase 9 as safety measure for Epo gene therapy 635
www.bjournal.com.br Braz J Med Biol Res 43(7) 2010
AIDS, myelodysplasia, or even hemoglobinopathies (14-18) 
could benefit from the delivery of erythropoietin (Epo) by 
gene therapy, particularly in diseases where resistance to 
Epo is important and administration of large doses of this 
hormone is necessary in order to obtain a response.
In view of its wide application, gene therapy using the 
Epo gene has been the aim of many in vitro and in vivo 
studies (19-28). Sufficient gene expression for a long-term 
response has been easily obtained in most in vivo studies 
and the target of erythropoietin treatment is reached when 
the hormone is delivered to the plasma by intramuscular 
injection of the vector or implant of encapsulated trans-
formed cells (19-28). The success of this approach has 
been demonstrated directly by hematocrit increase as well 
as by measurement of Epo protein in cell culture or in the 
serum of tested animals, such as mice, monkeys, and cats. 
However, the main side effects observed using nonviral or 
viral vectors for delivery of the gene are polycythemia and 
fatal thrombosis (19,20). Thus, the great challenge with this 
type of gene therapy is the achievement of down-regulation 
of Epo gene expression or the elimination of modified cells 
in cases of hemodynamic and rheologic problems associ-
ated with increased risk of thrombosis. 
Therefore, the effectiveness of the caspase-9-based 
artificial “death switch”, as a safety measure for gene 
therapy based on the erythropoietin hormone, was tested 




The following plasmids were used in this study: the 
murine dimeric Epo-encoding plasmid, ptet-mEpoD (25) 
(5 µg plasmid per 50 g weight), the tetracycline-controlled 
transactivator encoding, ptet-tTAk plasmid (0.5 µg/50 g; 
Gibco, France) (29), and pSH1/Sn-E-Fv’-Fvls-casp9-E, 
the iCasp9-encoding plasmid iCasp9 that consists of full-
length iCasp9 including its caspase recruitment domain 
(CARD; GenBank NM001 229) linked to two molecules of a 
12-kDa human FK506-binding protein (FKBP12; GenBank 
AH002 818) that contains an F36V mutation. For the in vivo 
studies, varying amounts of the iCasp9-encoding plasmid 
were used. The ptet-mEpoD plasmid was obtained by 
subcloning two PCR products of the complete murine Epo 
open-reading frame cDNA sequence, except for the stop 
codon, and except for the signal sequence, respectively, 
into the BS-KSII+ phagemid (Stratagene, Saint-Quentin, 
France), linked by a linker fragment encoding a peptide of 
9 residues (Gly-Ser-Gly4-Ser-Gly-Ala). The final construct 
was obtained by subcloning the ClaI-HindIII mEpoD frag-
ment from pBS-mEpoD in the ptet-splice plasmid (Gibco, 
France). The amounts of ptet-mEpoD and ptet-tTAk plas-
mids injected followed a previously described protocol (25). 
All plasmids were doubly purified using a cesium chloride 
gradient. The ptet-mEpoD and iCasp9 plasmids are rep-
resented in Figure 1. 
C2C12 cell lineage
Murine C2C12 myoblasts derived from the skeletal 
leg muscle of an adult C3H mouse were obtained from 
the American Type Culture collection (ATCC, CRL 1777, 
USA) and grown in Dulbecco’s modified Eagle’s minimal 
essential medium with 10% fetal bovine serum at 37°C in 
a CO2 incubator.
Stable transfections
Cells (5 x 105) were transfected with 20 µg iCasp9 and 
1 µg tpMC1neoPolyA (Stratagene, France) vector in 1440 
µL OptiMEM (Invitrogen Life Technologies, USA) and 60 µL 
lipofectamine (Invitrogen Life Technologies), according to 
manufacturer instructions. Genetically modified cells were 
selected with neomycin (Invitrogen Life Technologies) for 
2-3 weeks and the clones were then expanded and tested 
by PCR and Western blot.
Animals
Eighty-nine male C57BI/6 mice, 8-12 weeks old, were 
used in this study. All experiments were performed in agree-
ment with the Ethics Committee of the Biology Institute of 
the University of Campinas.
Plasmid injections and electric-pulse delivery
Anesthesia and muscle plasmid delivery were performed 
as described in Payen et al. (24). The animals were anesthe-
tized by an intraperitoneal injection of a mixture of ketamine 
(85.8 mg/kg) and xylazine (3.1 mg/kg) diluted in 150 mM 
NaCl. The vectors were injected into the tibial muscle of 
the animal in a final volume of 30 µL 150 mM NaCl using a 
Hamilton syringe. Electric pulses were delivered 30 s after 
injection using external plate electrodes placed on each 
side of the leg. As previously described, eight 20-ms and 
200-V/cm electric pulses were applied at 1 Hz frequency 
using an ECM 830 electroporator (BTX Molecular Delivery 
Systems, USA). 
Detection of the iCasp9 plasmid by PCR analysis
Genomic DNA obtained from stably transfected cells 
or animal muscles was subjected to PCR analysis using a 
pair of oligonucleotides designed in different exons, in order 
to give a fragment of 470 bp, specific for the detection of 
the iCasp9 plasmid. Sense (5’ CGG AAA CAC CCA GAC 
CAG TG 3’) and antisense (5’ CGA CAC AGG GCA TCC 
ATC TG 3’) primers were synthesized by Integrated DNA 
Tech (Coralville, USA) and the following PCR conditions 
were used: 35 cycles of 1-min denaturation at 94°C, 1-min 
annealing at 56°C and 1-min extension at 72°C, followed by 
a 5-min extension at 72°C. PCR products were run on 1.5% 
agarose gels and analyzed by staining with ethidium bromide 
and visualized using Kodak Digital Image 1D 3.0.2.
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Detection of iCasp9 expression by Western blot 
analysis
For protein extraction, cells were incubated for 30 
min at 4°C in lysis buffer containing 100 mM EDTA, 1% 
Triton in PBS, 0.5 M PMSF, 10 µg/mL aprotinin, 1 µg/mL 
leupeptin and centrifuged at 12,000 rpm for 20 min at 4°C. 
The supernatant was collected and frozen at -80°C. Equal 
amounts of protein were submitted to SDS-PAGE in a Laem-
mli system using 12% polyacrylamide. Western blots were 
carried out with a rabbit anti-caspase 9 polyclonal antibody 
(H-83, Santa Cruz Biotechnology, USA, 1/1000) and bands 
were developed with the ECL™ Western Blotting Analysis 
System (Amersham-Pharmacia Biotech, UK). 
CID
The inducer of dimerization used in the present study 
was AP20187 (kindly provided by ARIAD Pharmaceuticals, 
USA). The AP20187 (Ariad Pharmaceuticals Kit Argent™) 
stock solution was prepared by dissolving the compound in 
100% ethanol, at a concentration of 62.5 mg/mL and stored 
at -20°C. AP20187 was administered to the cell culture at 
100 nM final concentration. For in vivo studies, the AP20187 
stock solution was diluted in 2% Tween and PEG-400 to a 
final concentration of 0.25 mg/mL, and administered once 
intraperitoneally at the dose of 3 mg/kg. AP20187 was 
administered according to manufacturer instructions.
Doxycycline administration 
In order to test the efficiency of the control of Epo se-
cretion by doxycycline, despite co-adjuvant administration 
of iCasp9 and AP20187, 200 µg/mL doxycycline (Sigma, 
USA) was administrated in drinking water for 2 weeks to 2 
animals that received 5 µg/50 g ptet-mEpoD plasmid and 
0.5 µg/50 g ptet-tTAk plasmid and to 6 animals also injected 
with 6 µg/50 g iCasp9 plasmid.
Hematocrit determination
Hematocrit was determined weekly by a standard micro-
hematocrit method.
Plasma Epo measurement
Plasma Epo concentration was determined using an 
ELISA kit and mouse Epo standards both from R&D Sys-
tems (Oxon, UK). 
TUNEL assay 
For in vivo studies, paraffin sections were dewaxed, 
treated with proteinase K and then nick-end labeled us-
ing fluorescein-conjugated 12-dUTP and the enzyme 
terminal deoxynucleotidyl transferase (TdT) (Promega, 
USA). Sections were counterstained with 4’,6-diamidino-
2-phenylindole (DAPI) to locate nuclei. Nuclei containing 
fragmented DNA present bright white fluorescence with 
Figure 1. Structure of the ptet-mEpoD and iCasp9 plasmids used in the present study. A, The ptet-mEpoD plasmid contains two mol-
ecules of the complete murine erythropoietin (Epo) open-reading frame cDNA sequence linked by the peptide linker fragment encod-
ing 9 amino acid residues (Gly-Ser-Gly4-Ser-Gly-Ala), subcloned in the ptet-splice plasmid (Gibco, Cergy-Pontoise, France). B, The 
iCasp9 plasmid consists of the full-length inducible caspase 9 including its caspase recruitment domain linked to two molecules of a 
12-kDa human FK506-binding protein that contains an F36V mutation, under the control of the SR alpha promoter. 
A B
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contribution from both green (fluorescein) and blue (DAPI) 
staining. For the in vitro study, 5 x 104 stably transfected 
cells were treated with 100 nM AP20187. After 12 h, the 
TUNEL reaction was performed according to the same 
protocol, with the exception that nuclei were counterstained 
with propidium iodide, so that apoptotic nuclei appeared 
yellowish-orange, with contribution from both green (fluo-
rescein) and red propidium iodide. A positive reaction was 
attained by treating a tissue section with DNase I. For the 
negative control, the TdT enzyme was omitted from the 
incubation step. Images were obtained using an Olympus 
fluorescence microscope. 
Statistical analysis
Data are reported as medians. For each group of mice, 
variables were analyzed by the Wilcoxon-signed rank test 
and results were considered significant when P < 0.05.
Results
In vitro studies
Stable transfections. Since the in vivo studies were de-
signed to test the intramuscularly injected iCasp9 system, 
stable transfections in mouse myoblasts were performed. 
Thirty-nine clones of C2C12 myoblasts transfected with 
iCasp9 were selected with the antibiotic neomycin. Using 
the PCR technique it was possible to detect the presence 
of the integrated transgene in 27 of these clones (Figure 
2A). Western blotting using the anti-caspase 9 antibody 
for the detection of human caspase 9 revealed a chimeric 
protein with a molecular weight of ~70 kD, corresponding 
to 46 kD of the human caspase 9 and 12 kDa of each mol-
ecule of FKBP12, in 6 clones. Clones 1 and 3 (Figure 2B) 
were selected for CID treatment using 100 nM AP20187. 
The TUNEL assay was performed 12 h after treatment and 
most cells analyzed were positive (clone 1 treated - 88%, 
untreated - 3%; clone 3 treated - 78%, untreated - 5%). 
Figure 2C shows a representative field of clone 1, treated 
and untreated. These results demonstrate that the iCasp9 
plasmid may be expressed in mouse myoblasts and pres-
ents a good response to CID. 
In vivo studies
The design of Experiments 1 and 2 is represented in 
Figure 3.
Experiment 1 
Definition of quantity of iCasp9 vector administration. In 
order to test the amount of iCasp9 to be injected in the ani-
mals without compromising the expression of the Epo vector, 
3 groups of 11 mice each were studied. Animals belonging 
to the three groups received 5 µg/50 g ptet-mEpoD and 0.5 
µg/50 g ptet-tTAk plasmids, while animals from groups 2 
and 3 also received 6 and 10 µg/50 g of iCasp9-encoding 
plasmid, respectively. In order to standardize the amount 
of plasmid injected to 15.5 µg/50 g, animals from groups 1 
and 2 also received naked plasmid (without the FKBP and 
caspase 9 cDNA). Hematocrit and Epo were determined 
prior to the plasmid injection.
Four weeks after plasmid injection there was a significant 
increase in hematocrit in the mice injected with the mEpo 
plasmid, as shown in Figure 4. The median hematocrit 
Figure 2. Caspase 9 activity was induced 
by AP20187 in iCasp9 C2C12 modified 
cells. A, PCR showing the presence of 
the iCasp9 plasmid in 2 clones (lanes 1, 
2) and the absence in 2 negative controls 
(lanes 3, 4). In the following lanes, water 
(H2O) or plasmid (C) was used instead 
of cell line DNA. MW = ladder 100 bp; B, 
Western blot showing expression of cas-
pase 9 and FK506-binding protein (FKBP) 
(~70 kD) in clones 1 and 3. Cell extracts 
were run on 12% SDS-PAGE and immu-
noblotted with anti-caspase 9 antibody. 
C, TUNEL-positive cells detected after 
AP20187 treatment (left side). Untreated 
cells were used as a control (right side). 
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value increased by 33% above baseline in group 1 (Mann-
Whitney test, median difference = 20.0, 95% confidence 
interval (CI) of the difference = 8.26-25.01; P = 0.0013), 
while the median hematocrit increased by 36.8% in group 
2 (median difference = 17.5, 95%CI of the difference = 
10.24-26.59; P = 0.0004), and by 12.8% (median difference 
= 4.5, 95%CI of the difference = 0.45-12.38; P = 0.0374) 
in group 3. Thus, we concluded that 6 µg iCasp9 did not 
reduce Epo vector efficiency, but an opposite result was 
obtained with 10 µg iCasp9.
Detection of TUNEL-positive cells in the injected muscle 
after AP20187 administration. Two animals from group 
1 (injected with 5 µg/50 g ptet-mEpoD and 0.5 µg/50 g 
ptet-tTAk), 6 animals from group 2 (injected with 5 µg/50 g 
ptet-mEpoD, 0.5 µg/50 g ptet-tTAk and 6 µg/50 g iCasp9 
plasmids), and 4 mice from group 3 (injected with 5 µg/50 
g ptet-mEpoD, 0.5 µg/50 g ptet-tTAk and 10 µg/50 g iCasp9 
plasmids), which reached hematocrits of more than 65%, 
were selected for CID treatment and muscle biopsies. 
Four weeks after plasmid injection, they were treated with 
AP20187. All animals were sacrificed for muscle studies 
24 h after treatment. Plasma Epo was greatly and signifi-
cantly increased in all of them and the iCasp9 plasmid was 
detected by PCR in the muscle of the 10 animals injected 
with it (data not shown). A TUNEL assay showed positive 
cells in the muscle of 3 of 6 animals from group 2 and in 3 
of 4 animals from group 3 (Figure 5). None of the animals 
from group 1 showed TUNEL-positive cells. Thus, we con-
cluded that 6 µg/50 g iCasp9 is able to trigger apoptosis 
after AP20187 induction.
Experiment 2
Capacity of iCasp9 and CID to regulate Epo vector 
expression. Since 10 µg/50 g iCasp9-encoding plasmid 
decreased the Epo plasmid efficiency, 6 µg/50 g iCasp9-
encoding plasmid was injected in the next experiment. 
The experiment was repeated with two groups of animals. 
Animals from group 1 (N = 20) were injected with 5 µg/50 
g ptet-mEpoD, 0.5 µg/50 g ptet-tTAk plasmids and 6 µg/50 
g naked plasmid, and mice from group 2 (N = 36) were 
injected with 5 µg/50 g ptet-mEpoD, 0.5 µg/50 g ptet-tTAk 
plasmids and 6 µg/50 g iCasp9 plasmid. Before plasmid 
injection, the median basal hematocrit was 51% (range: 49 
to 55%) and 52% (range: 48 to 58%) for groups 1 and 2, 
respectively. Basal Epo levels ranged from 2.7 to 4.9 mU/
mL (median = 4.6 mU/mL) for group 1 and from 2.4 to 5.3 
mU/mL (median = 4.3 mU/mL) for group 2.
In group 1, 4 weeks after plasmid injection, 14 of 20 
animals (70%) presented an increase in hematocrit rang-
ing from 65 to 83% (median = 69.24%; Figure 6). All 14 
animals received AP20187, 4 weeks after plasmid injection. 
In order to test the efficiency of the control of Epo secre-
tion by doxycycline, despite co-adjuvant administration of 
iCasp9 and AP20187, doxycycline was administered as 
described in Material and Methods to 2 animals for 2 weeks, 
starting 8 weeks after plasmid injection. The remaining 12 
animals sustained their hematocrit above 65% for over 15 
weeks (Figure 6) and Epo levels above 90 mU/mL for at 
least 8 weeks, and reached levels as high as 298 mU/mL 
(Figure 7).
In group 2, 1 animal died after plasmid injection and 
electropulse and 2 animals died 10 days later. Interest-
ingly, these 2 animals had a rapid and relatively large 
increase in hematocrit (data not shown), which reached 
74 and 76%, 1 week after plasmid injection. Four weeks 
Figure 3. Schematic representation of the in vivo studies. Hct - 
hematocrit; Epo = erythropoietin.
Figure 4. Six micrograms of iCasp 9 plasmid does not reduce 
erythropoietin (Epo) vector efficiency. Hematocrit before and 4 
weeks after intramuscular injection of 5 µg ptet-mEpo/0.5 µg ptet-
tTAk plasmids, without or with 6 and 10 µg iCasp9 plasmid. The 
Wilcoxon-signed rank test was used for statistical analysis.
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after plasmid injection, hematocrit increased above 65% 
in 23 of 33 mice (64%; Figure 8A). In these 23 animals, 
Epo levels ranged from 53 to 234 mU/mL (median = 138 
mU/mL; Figure 8B). These 23 animals were selected for 
AP20187 administration (CID). Two weeks after AP20187 
administration, 7 animals (30.44%) presented a significant 
reduction in hematocrit and plasma Epo (Wilcoxon test). 
In these 7 animals, hematocrit at week 15 (Figure 9A) 
ranged from 52 to 65% (median = 54%) and plasma Epo 
levels (Figure 9B) at week 8, ranged from 2.6 to 46 mU/
mL (median = 4.2). Sixteen animals did not respond to the 
drug (69.56%) and, 4 weeks after CID injection, 6 of them 
were also selected for doxycycline administration. Animals 
that did not respond to CID and that were not treated with 
doxycycline (N = 10) sustained a hematocrit above 78% for 
more than 15 weeks (Figure 9C), as well as above normal 
Epo levels (Figure 9D) that ranged from 90 to 251 mU/mL 
(median = 159 mU /mL).
In summary, experiment 2 demonstrated that the Epo 
vector efficiently induced a significant and sustained in-
Figure 5. AP20187 induces apoptosis of muscle injected with iCasp9 and 5 µg ptet-mEpo/0.5 
µg ptet-tTAk plasmids. A and C show negative TUNEL reactions in 2 animals not injected with 
the iCasp9 plasmid. B and D show positive reactions (indicative of apoptosis) in 2 animals injected 
with the iCasp9 plasmid. Muscle biopsies were performed 24 h after AP20187 treatment.
Figure 7. The erythropoietin (Epo) vector induces high levels of 
plasma Epo. In the animals with hematocrits above 65%, plasma 
Epo levels (R&D ELISA kit) demonstrated large increases after 
Epo plasmid injection that were maintained for at least 4 weeks. 
*P < 0.0001 compared to 0 week (Wilcoxon-signed rank test). 
Figure 6. The erythropoietin (Epo) vector induces a large he-
matocrit increase in 70% of the animals. Hematocrit before and 
after intramuscular injection of 5 µg ptet-mEpo/0.5 µg ptet-tTAk 
plasmids showed that 30% of the animals (N = 8) did not present 
a hematocrit increase of more than 65%. Ten animals sustained 
the hematocrit above 65% for over 15 weeks. 
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crease in hematocrit and Epo levels even in the presence 
of iCasp9 plasmid. It also showed that AP20187 induced 
the iCasp9 system and regulated Epo vector expression 
in 30% of the animals.
Effect of iCasp9 and CID on the regulation of Epo secre-
tion by doxycycline. The 2 animals from group 1 and the 6 
animals from group 2, selected for doxocycline administra-
tion as described above, showed a significant reduction 
Figure 8. Six micrograms iCasp9 plasmid did not reduce the efficiency of the erythropoietin (Epo) plasmid. A, Hematocrit before and 4 
weeks after Epo plasmid injection in animals that also received the iCasp9 plasmid; 70% (N = 23) of the animals obtained a hematocrit 
increase of more than 65%. B, Plasma Epo levels were significantly increased in these 23 animals, 4 weeks after plasmid injection 
(Wilcoxon-signed rank test). 
Figure 9. The iCasp9 system was induced efficiently by AP20187 in 30% of the animals. Twenty-three mice received 5 µg erythropoi-
etin (Epo) vector/50 g, 0.5 µg ptet-tTAk/50 g and 600 µg/50 g iCasp9 plasmids. Two weeks after AP20187 administration, 7 of them 
(30.4%) showed a significant reduction in hematocrit (A) and Epo levels (B) (*P < 0.03, Wilcoxon-signed rank test). Sixteen animals 
(69.6%) did not respond to chemically induced dimerization (CID). Six of these were selected for doxycycline administration and the 
remainder (N = 10) sustained their hematocrit above 78% for more than 15 weeks (C), as well as high levels of Epo (D).  
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in hematocrit and plasma Epo levels, 1 week after the 
beginning of doxycycline administration. Lower hematocrit 
and plasma Epo levels were reached after 3 weeks. No 
significant difference in hematocrit (Figure 10A and C) or 
plasma Epo levels (Figure 10B and D) was detected when 
comparing groups 1 and 2. Thus, we concluded that doxy-
cycline efficiently regulated Epo secretion in the presence 
of the iCasp9 plasmid and AP20187 administration.
Detection of the iCasp9 vector in the injected muscle. 
PCR for the detection of the iCasp9 plasmid was performed 
in all mice from group 2, except for the 3 mice that had died 
earlier. The iCasp9 plasmid was not detected in 10 animals, 
and none of these responded to CID administration. The 
plasmid was detected in the remaining 23 animals, includ-
ing 6 mice that did not respond to AP20187 administration 
(data not shown). Thus, we concluded that the absence of 
a response to CID could be related to a low copy number 
of the iCasp9 vector. 
Discussion
Therapeutic proteins may be delivered by gene therapy. 
The most promising results in this field have arisen from 
the treatment of hemophilia B patients with adeno-associ-
ated virus vectors expressing factor IX (11,12). Increasing 
evidence emerging from in vivo studies demonstrates that 
erythropoietin is another protein that may be used in gene 
therapy with benefits to a large number of patients. The 
high cost of recombinant hEpo restricts its correct use, 
since hospital administrators only allow administration of 
hEpo when severe anemia is already established. In most 
developing countries, hEpo, at low doses, is approved only 
for renal failure, preventing the use of higher doses of hEpo 
to treat diseases in which Epo resistance is common (such 
as myelodysplasia, hemoglobinopathies or cancer). Thus, 
gene therapy may reduce the cost of treatment and return 
the therapeutic decision to doctors and patients, rather than 
to payers, as already mentioned by Lippin et al. (26).
Most studies using viral or non-viral vectors carried out 
in mice or non-human primates, and recently in patients 
with chronic renal failure, have shown that erythropoetin 
gene therapy leads to therapeutically relevant levels of 
the Epo hormone (26,30). However, an undesirable side 
effect of this therapy could be polycythemia and the risk 
of thrombosis (19,20). Autoimmune anemia has also been 
described due to the appearance of neutralizing antibod-
ies against endogenous Epo (20,31). Preliminary in vivo 
studies of the regulation of Epo secretion by oxygen seem 
promising, but few studies have been carried out in this field 
(28,32,33). Regulation of Epo secretion by doxycycline is 
Figure 10. The iCasp9 system permitted efficient induction of the Tet-off system by doxycycline. Doxycycline was administered in 
drinking water for two weeks to 2 animals injected with 5 µg Epo/0.5 µg ptet-tTAk (group 1) and to 6 animals also injected with 6 µg 
iCasp9 plasmid (group 2). Similar reductions in hematocrit and Epo levels were observed when comparing group 1 (A, B) and group 2 
(C, D). The data for the 2 mice in Panel A and the 6 mice in Panel C are presented with the same symbols. 
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possible and seems efficient (19,25) and has been observed 
in non-human primates when the immune system is not 
mobilized against the tetracycline-dependent transactivator 
(34). However, if a definitive gene switch is necessary to 
repress expression, the patients would need to be continu-
ally on medication. Thus, a fail-safe method to switch off 
the gene therapy would be to destroy the modified cells by 
triggering apoptosis. 
Besides the expected low efficiency of gene therapy us-
ing non-viral vectors, these do not integrate in the genome 
and there is extremely little, if any, risk of cancer using this 
strategy. Moreover, viral vectors have also been associated 
with low levels of protein expression, as observed in gene 
therapy for hemophilia (35) or, more recently, for chronic 
renal failure (26), probably due to immunogenic reactions 
against the gene vehicle. Thus, in our study we decided to 
test induction of apoptosis for safety in gene therapy, using 
non-viral vectors as a platform. Erythropoietin was used in 
this study and the therapeutic gene and safety measure 
used was the inducible caspase 9 gene (iCasp9), which 
was regulated by the AP20187 CID. Compared to caspases 
3 and 7, iCasp9 is expressed at sufficient levels to confer 
sensitivity to CID (36,37). This system has low potential 
immunogenicity and the CID has no side effects (38). 
Therefore, pharmacological studies of AP20187 suggest 
widespread bioavailability. 
In order to obtain sustained and regulated levels of Epo, 
in our in vivo studies we electro-transferred into mouse 
skeletal muscle the already successfully tested dimeric 
murine Epo-Epo plasmid containing the tetO element and a 
plasmid encoding the tetracycline-controlled transactivator 
(25,29). This system works very well in mice and doxycycline 
efficiently controlled the secretion of dimeric Epo without 
inducing antibody formation. Therefore, high efficiency of 
gene transfer by electric pulse has been demonstrated in 
vivo (39,40). In our studies, the efficiency of the mEpoD 
plasmid in animals receiving or not 6 µg iCasp 9 plasmid 
was observed in about 70% of the animals of both groups 
and was sustained for at least 15 weeks. However, no 
increase in plasma Epo levels or hematocrit was observed 
in 30% of the animals from the two groups. This failure may 
be due to several factors, including the inefficient transfer 
of the plasmid to the muscle cells, failure in the expression 
of the protein or even an immune reaction caused by the 
electropulse (25,39,40). 
In the present study, we also observed a low response 
to the Epo vector in mice receiving 10 µg iCasp9, suggest-
ing that CID-independent basal toxicity may have reduced 
survival of Epo plasmid-transduced cells. In fact, iCasp9 has 
a much lower basal activity than FAS and iCaspase8, but 
always maintains a low basal activity due to overexpression 
(3). However, cells that overexpress iCasp9 at toxic levels 
will be destroyed early due to autoactivation of caspase 
9, leaving a stable cohort of cells that are still sensitive to 
CIDs (9). On the other hand, any cells expressing levels of 
iCasp9 too low for activation will probably express irrelevant 
levels of Epo. Thus, there should be a “therapeutic window” 
in which iCasp9 could be useful. 
The gene expression control by the EPO doxocycline 
induction system used in this study has been well docu-
mented in the literature (28) and was reproduced here in 2 
animals. We also showed that the efficiency of doxycycline 
administration in controlling Epo secretion was similar in 
the group of animals receiving the iCasp9 vector, according 
to hematocrit and plasma Epo measurements. Thus, we 
concluded that iCasp9 may be used as a safety mechanism 
in combination with other vectors, without interfering with 
gene therapy efficiency. 
Regarding the efficiency of the iCasp9 plasmid in induc-
ing apoptosis, 30% of the animals that received the iCasp9 
vector responded to AP20187 administration. In these 
animals, the iCasp9 vector was very efficient in inducing 
apoptosis since Epo levels and hematocrit reached basal 
levels in less than 4 and 6 weeks, respectively, after CID 
administration. TUNEL-positive cells were detected in the 
muscle of two animals injected with the iCasp9 plasmid 
and treated with CID.
Failure in efficiently capturing the iCasp9 plasmid by the 
muscle cells, a low copy number of the vector or inadequate 
CID concentration or distribution may have contributed to 
the low efficiency of the system in these initial studies. The 
activation of iCaspase9 by a synthetic dimerizing drug is a 
strategy that can be used to destroy transformed cells and 
to control undesirable side effects of gene therapy, although 
more studies are necessary to improve this technique.
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